Woman exercising in a park as part of a medical weight-management programme
● Doctor-led medical weight loss Close-up horizontal Wegovy, Mounjaro and Ozempic injection pens

Weight-loss injections in Spain, with a doctor throughout

English-speaking doctor assessment, prescribing when suitable and structured follow-up—by telephone or secure video.

Free one-minute pre-checkEligibility before booking English-speaking doctorTelephone or secure video E-prescription by emailREMPe, when appropriate Ongoing follow-upDosage, progress and side effects
Dr Ben Harry Clegg, medical reviewer
Clinically reviewedDr Ben Harry CleggMálaga registration 292911940 · Last reviewed 10 August 2026
Registered Spanish medical centreNICA 55712
Start in the right place

Choose your next step

Use the route that matches where you are now. Prescribing always follows an appropriate doctor assessment.

New to treatment

Check eligibility first

Answer the main BMI and safety questions before choosing an appointment.

Already taking treatment

Book a doctor review

Bring your medicine, current dose and evidence of your treatment history.

Comparing medicines

Understand the differences

Compare Wegovy, Mounjaro and Ozempic indications, dosing and monitoring.

Compare treatments
Stable ongoing treatment

Prescription renewal

Use the repeat-prescription route when treatment and dosage are already established.

Repeat-prescription route
Woman checking her weight with scales and measuring tape
Could treatment be suitable?

Eligibility starts with BMI—but does not end there

The doctor reviews BMI, weight-related conditions, previous treatment, current medicines, pregnancy plans and safety exclusions.

BMI 30+ Common assessment range
BMI 27+ May be considered with a relevant weight-related condition
How care works

From first assessment to stable treatment

01

Pre-check

Complete safety and eligibility questions.

02 📅

Book

Choose the €39 consultation.

03 🩺

Doctor review

Discuss history, goals and dosage.

04 📨

Prescription

QR e-prescription if clinically suitable.

Follow-up

Progress is reviewed in context

Prepare your current weight, appetite changes, side effects and any new medicines. The aim is the lowest effective dose that supports progress with manageable side effects.

  • Monthly review while dosage is adjusted
  • Side-effect prevention and management
  • Nutrition, hydration and activity guidance
  • Longer intervals may be discussed once stable
Wegovy dose escalation overview
Wegovy dosage escalationUsual staged pathway—clinical review determines whether and when the dose changes.
Mounjaro dosage escalation
Mounjaro dosage escalation overview from 2.5 mg to 15 mg
Six available stages—patients do not automatically progress to the maximum dose.
Patient having an online medical weight-management consultation Online medical weight-management consultation
Is a physical appointment necessary?

No physical appointment is normally needed, although local examination or tests may be recommended.

Is a prescription guaranteed?

No. Prescription follows only when the doctor confirms clinical suitability.

How often is follow-up?

Usually monthly during dose adjustment.

What side effects are common?

Nausea, diarrhoea, constipation and vomiting are commonly discussed.

Can I switch provider?

Yes; bring evidence of current medicine, dose and treatment history.

Can I travel with the pen?

Storage instructions differ by medicine and pen type.

Which medicine is best?

The doctor considers indication, medical history, previous response and safety.

Is Ozempic a weight-loss medicine?

Ozempic is authorised in the EU for type 2 diabetes. Wegovy is the semaglutide brand authorised for weight management.

Prescription pathways by location

Weight-loss medication prescriptions across Spain

Read the complete prescription process or choose a city, island or local area for practical pharmacy, nearby-area and travel guidance.

Dr Ben Harry Clegg
Medically reviewed

Dr Ben Harry Clegg

General practitioner · Málaga registration 292911940 · Nerja Medical Center NICA 55712

Clinical review date: 9 August 2026

Meet the telehealth medical team